Heterologous Expression of Pneumocystis Surface Proteins for Antigen Discovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The inability to culture Pneumocystis jirovecii and lack of a sequenced genome hinder antigen discovery for developing effective vaccines and diagnostic methods against Pneumocystis pneumonia, a life-threatening infection in immunocompromised patients.
Innovation Solution
A method for surface proteomics of Pneumocystis murina that identifies conserved surface proteins, including Meu10, GSC-1, Ght5, Erg6, ATP2, Gas4, and Mfs1, which are used to elicit immune responses, generate therapeutic antibodies, and diagnose Pneumocystis pneumonia by administering these proteins or their nucleic acids, or using monoclonal antibodies specific to them.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antigen discovery methods are used, then conventional therapeutic options are limited, but the inability to culture Pneumocystis in vitro and lack of sequenced genome hinder antigen discovery
Solution Approach 1:
The patent uses a heterologous expression system where Pneumocystis antigens are expressed in a different host system (e.g., bacterial, yeast, or mammalian expression systems) that can be cultured in vitro. This intermediary approach allows antigen production without requiring culture of the actual Pneumocystis organism, thereby resolving the contradiction between therapeutic effectiveness and discovery complexity.
Solution Approach 2:
The patent creates copies of Pneumocystis antigens through molecular cloning and heterologous expression. By synthesizing and expressing antigen proteins in alternative systems, the invention enables antigen discovery and vaccine development without needing to culture the original unculturable pathogen, thus overcoming the genome sequencing and culture limitations.
2Adaptability or versatility
If limited alternative therapeutic choices are used, then treatment options are constrained, but developing new therapies requires overcoming culture limitations
Solution Approach 1:
The patent employs heterologous expression systems as intermediaries to produce Pneumocystis antigens. These alternative expression systems (bacterial, yeast, or mammalian cells) can be easily cultured and manipulated, providing a practical manufacturing platform that diversifies therapeutic options while maintaining ease of production.
Solution Approach 2:
The patent changes the production parameters by moving from in vivo Pneumocystis culture to in vitro heterologous expression systems. This parameter change includes altering the host organism, cultivation conditions, and expression methodologies, thereby enabling diverse antigen production with improved ease of manufacture and therapeutic versatility.
3Reliability
If antibody responses to surface proteins are used for protection, then immune protection can be achieved, but antigen discovery is hindered by inability to culture the pathogen
Solution Approach 1:
The patent creates copies of surface proteins through molecular cloning and heterologous expression. By producing antigen copies in culturable systems, researchers can identify and characterize surface proteins that elicit protective antibody responses without needing to culture the actual Pneumocystis organism, thus resolving the detection difficulty while maintaining protection efficacy.
Solution Approach 2:
The patent uses heterologous expression systems as intermediaries to produce and identify surface proteins. These intermediary systems allow for the detection, characterization, and validation of antigens that induce protective immune responses, overcoming the limitation of being unable to directly study surface proteins from unculturable Pneumocystis.
Data Source
AI summary
Pneumonia due to the fungus Pneumocystis jirovecii is a life-threatening infection that occurs in immunocompromised patients. The inability to culture the organism as well as the lack of a sequenced genome has hindered antigen discovery that could be useful in developing effective vaccines, therapeutic antibodies and diagnostic methods. A method of surface proteomics of Pneumocystis murina that reliably detects surface proteins that are conserved in Pneumocystis jirovecii is described. In particular, eight identified P. murina surface proteins are described. Methods of eliciting immune responses against the identified proteins, generating therapeutic antibodies against the identified proteins, as well as diagnostic methods based on the identified peptides are described.